SEOUL, KOREA - Huons announced on May 14 that its consolidated operating profit reached 6.8 billion won in the first quarter of this year, up 22.8 percent from a year ago.Sales and net profit stood at 41.4 billion won and 5.3 billion won, respectively, up 21.6 percent and 19.6 percent from a year ago.
Huons’ annual sales have sustained a double-digit growth over the past 15 years, reaching 158.1 billion won last year.
Considering that Huons achieved a 20 percent-level growth in all of sales, operating profit and net profit in the first quarter, expectations are growing that it could join the 200 billion won annual sales club this year.
The company attributed the strong first-quarter sales to the hike in sales of the locally developed hyaluronic acid filler Elravie and the rising popularity of Selenase, a drug used to strengthen the immune system.
In particular, the sales of Kynix 1 and 2 Eye Drops which contain no preservatives, which are selling through a multinational pharmaceutical company Alcon, jumped 33.8 percent year on year thanks to the increasing inflow of fine dust from China and the increase in the use of smartphones.
